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     There are more than 350 million individuals with hepatitis C in the world. One of the important problems 
in vaccine project is development of effective and suitable adjuvant in human vaccines. At present research 
we applied human βHsp90 protein as an adjuvant in recombinant HCV vaccine design. The thermal vector 
of pGP1-2 was used for human heat shock protein 90 expression. This protein injected to BalbC mice as an 
adjuvant together with recombinant protein of HCV core. The combination of these proteins was used and 
we evaluated the humoral and cellular immunity and the cytokine secretion of inguinal and popliteal lymph 
nodes lymphocytes were analyzed in vitro and ex vivo conditions. So the combination of Core protein 
together with hsp90 induced total IgG and IgG2a secretion. The spleen lymphocytes proliferation were 
increased equal to serum IgG2a level that was constant in second time bleeding with significant different to 
complexes with freund’s adjuvant. At first IL-4 and IL-5 cytokines were increased, after one week it 
decreased. Production of IL-4 showed there was no hypersensitivity reaction after vaccine injection. 
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INTRODUCTION 
     It was estimated that about 350 million with 
hepatitis C virus (HCV) [1, 2].This virus are the 
most common cause of liver diseases. It can be 
transmitted parenterally, sexually and prenatally 
[1]. Search for new adjuvant, able to selectively 
trigger protective antibody production [3], is one 
of the important approaches in this study. 
However peptides bound to heat shock proteins 
(HSPs) of microbial or mammalian origin have 
been shown to elicit potent antigen-specific 
immunity. Also some of them, such as hsp60, 
hsp70, hsp90 and gp96 act as danger signaling 
molecules [4]. The ability of HSPs to facilitate the 
cross-presentation of MHC class I restricted 
epitopes and to prime CD8 cell effectors 
responses has been well established [5].CD4+ 
Tcells are important in shaping adaptive immune 
effectors like B cells and CD8+ T cells. The 
difference between spontaneous resolving and 
chronic persistence seems to lie on the quality of 
the CD4+ Tcell response [6]. The main purpose 
of this study was to elucidate immune responses 
induction, associated with formulation of the 
antigen and human Hsp90 as adjuvant.  
 
MATERIALS AND METHODS 
The Cells, bacterial strains, plasmids and 
laboratory animals: 
    The THP-1 cell line and BalbC mice were 
obtained from the Pasteur Institute of Iran. 
Escherichia coli strains Nova Blue and DH5α 
were purchased from Invitrogen, USA. pTZ57R 
(Fermentas, Germany), pGPhsp90 (constructed in 
our before study) and pETDuet-1 were plasmids 
which were used in this study.   
 





Cloning and Expression of HCV core protein: 
The plasmids pCgemex-1[7] was used to generate 
the HCV core PCR product by using below 
primers:  
CoreF5’CATATGAGCACACTTCCAAAACCCC3’,Co
reR 5’CTCGAGCGCGGAGGCTGGTGTTGTAAG3’.  
To express interested protein, the PCR product was 
inserted into pETDuet-1 expression vector after 
digestion with NdeI, XhoI restriction enzymes. 
Protein expression induction of HCV core was 
carried out by 1 mM IPTG at 37° C. Hsp90 protein 
expression was induced by 42°C after 5 hours 
.Confirmation of these proteins were carried out by 
western blotting and gel diffusion with mixed 
patients sera  and monoclonal antibodies of tag 
peptides[8]. 
Study of biological activity of HCV core protein 
Macrophages and dendritic cells are the major 
sources of IL-12 produced during an inflammatory 
response. Thus the suppression of IL-12 by HCV 
core might be due to a direct interference with 
Mφ/DC activation by these antigens [9]. So at first 
THP-1 monocyte cell line was inoculated in RPMI 
medium (10% FBS, 100μg streptomycin, 100unit 
penicillin). Then the cells were transferred to 24-
well plates, 20000 cells in each well. After 6h   they 
were induced to macrophages by 250 ng PMA. 
These mature cells were incubated for 24h at 37 
̊ C in 5% Co2. To induce the IL-12 production by 
Mφs, 250 ng/ml Escherichia coli LPS was added to 
half of the wells. After 24h ELISA assay (Duoset 
ELISA kit, R&D) was carried out for study of IL-
12 production changes. 
Immunization of mice with HCV core protein  
After confirmation of the biological activity of 
produced protein, mice were immunized with 10μg 
protein with either equal volumes of freund’s 
complete adjuvant (sigma, USA) or in mixture with 
5 μg purified rhsp90 [8] by subcutaneous injection 
into the footpads. Control mice were immunized 
with FCA, rhsp90, LPS and PBS alone. The 
injection volume was adjusted to 50 μl. The mice 
were grouped as below: 1- HCc + FA, 2- HCc+hsp, 
3- Subcutaneously HSP90, 4- Subcutaneously PBS,  
5- Subcutaneously FCA. The mice were injected 
three times with 10 days intervals. Determination 
of antibody production in serum and supernatant of 
cultured lymphocytes of lymph nodes: Sera of 
immunized mice were collected on 7 and 14 days 
after immunization. Preimmune sera were used as 
controls. The total IgG, IgG2a antibodies were 
detected using mouse IgG2a and IgG ELISA 
quantitation kit (Bethyl, TX).  The lymphocytes of 
popliteal and inguinal lymph nodes lymphocytes in 
injected mice  were prepared 14 days after 
immunization using ficoll 700(Gibco,UK). The 
lymphocytes layer were suspended in RPMI 
(Gibco, UK) supplemented with 10% fetal calf 
serum, 100IU/ml penicillin and 100μg/ml 
streptomycin. Then for priming the lymphocytes 
10μg of protein, PBS, PHA (Gibco, UK) as 
controls were further added to the culture medium. 
The cells were incubated for 24 hours at 37 ̊ C in 
a humidified atmosphere with 5% CO2. 
Supernatants were collected after 24 and 48 hours.  
Cytokines assay 
The IL-5, IL-4 and IFNγ cytokines were analyzed 
in the supernatants of the lymphocyte cultures by 
mouse cytoset ELISA kits (invitrogen, Germany) 
regarding manufacture protocol. 
Statistical analysis 
Standard deviation was calculated using SPSS16 
software and ANOVA analysis. 
 
RESULTS 
Sub cloning and expression of HCV core fragment 
was carried out which results were shown in 
figures 1 and 2.  
Serum Antibody analysis by ELISA test 
The serum antibodies of mice were analyzed on 7 
and 14 days after injection. Pre-immune sera were 
used as controls. According to below curves, 
antibody against recombinant core protein in 
combination with Freund’s adjuvant in secondary 
response has been decreased. Also serum IgG2a 
level in group which hsp90protein used as adjuvant 
was significant (Pv<0.005).  So lymphocytes 
proliferation was depend on antigen effect and 
their activity was shown with IgG2a production in 
serum (Fig.3).  
 






Figure 1: a) 573bp HCV Core PCR product (a), 100bp DNA 
Ladder (b) 
b) Cloning confirmation of HCV core fragment by restriction 
analysis (NdeI, XhoI) 
 
 




Evaluation of IL-4, IL-5 and IFN-γ cytokines in 
lymphocytes culture supernatant 
In group immunized with combined protein with 
hsp90 adjuvant compared with freund’s, IL-4 
production is significant.  According to below 
curve reduction of IL-4 production in second step 
showed that there wasnot any allergic reaction 
against of vaccine injection. Hsp90 in 
combination with HCV core protein had positive 
effect on inguinal and popliteal lymph nodes 
lymphocytes for IL-5 production and stability of it 
in second step. IFN-γ production after hsp90 
injection as adjuvant and stability of it in inguinal 
lymphocytes culture were shown in below curve 
(Fig. 4, 5). After 48 hours, Hsp90 was an effective 
adjuvant in each of three organs’ lymphocytes and 
it recorded by IL-5 and IgG2a production 
(Pv<0.05). It showed excellent systemic 
immunity responses. 
                                                                                                                         
 
 
Figure 3: Comparison of adjuvant effect of Hsp90 and 
freund’s in IgG total and IgG2a production against of Core 
Ag     after 24(1) and 48(2) hours 




Figure 4:  Comparison between IFN-γ (pg/ml) in 
groups with combination of Core protein and 
Hsp90 or Fround’s adjuvant after 24h  
 
 






 Figure 6: Comparison between Core protein mixed 
with hsp90 or fround’s adjuvant injected groups for IL-
5 production (pg/ml) after 24h (i1) and 48h (i2)  
 
DISCUSSION 
     Viral hepatitis infections associate with 106 
annual mortality rate in human population, globally 
[10] In spite of vaccination in the different areas 
there are several reports about patients who got 
vaccine before. Also there is not efficient vaccine 
against of hepatitis C and one of the problems in 
vaccine project is development of effective and 
suitable adjuvant in human vaccines. The main 
purpose of this study was antibody production and 
cytokine variation against recombinant core protein 
mixed with rhsp90 as adjuvant compared with 
fround’s. There are many reports implying that 
chaperones may act as immunological adjuvant 
and could trigger potent cellular immune responses 
against intracellular pathogenic agents. Among 
broad family of chaperone proteins, beta subunit of 
human heat shock protein 90 was considered as 
adjuvant counterpart of the vaccine. HCV core 
protein was considered as immunogenic 
counterparts of the vaccine. Serum antibodies 
against HCV core protein epitopes (residues 7-21, 
31-45, 49-63, 99-113) have been demonstrated in 
HCV patients [11]. Due to contribution of all 
amino acid residues to form exact conformational 
epitopes, total of 191 amino acids were included in 
the vaccine preparation. Epitope specific T cell 
clones, produced through application of the 
vaccine, are able to recognize and act against virus 
infected cells.  In 2004, Doody et al, have revealed 
that a glycoprotein of 96 KD contributes to 
refolding of MHC-I and MHC-II molecules and to 
appropriate presenting of antigens and also results 
in differentiation of T CD8+ cells to effectors ones. 
To escape unwanted derivative and destructive 
outcomes of freunds' adjuvant, many scientists are 
seeking for an alternative strong and polarizing 
adjuvant appropriate for use with viral vaccines 
[12]. Several studies for evaluation of immune 
responses elicited by HCV core protein have been 
done, including, identification of core protein 
specific cytotoxic T lymphocytes [13]. Also Wen 
Li et al, in their study on 2006, Canada, have 
demonstrated high expression of pro inflammatory 
cytokines, stimulation of T cells and presence of 
Dendritic cells of expressing HCV-core Ags or 
NS3 proteins [14].According to the patent, 
numbere WO/2005/025614, injecting dose of the 
adjuvant to simultaneous application was one 
fifteenth of each of recombinant antigen.  
Our findings showed that, as a potent 
immunostimulant, freund’s compound could be 
replaced by HSP protein in the future vaccine 
formulations. Preliminary increased levels of IL-4 
imply proper humoral immune stimulation in the 
first encounter and following decrease of the 
cytokine means no hypersensitivity reactions could 
occur. Increased IL-5 levels in the study 
appropriately are related with the antibody levels, 
also increased concentration of the cytokine in 
inguinal lymphocytes culture are related to enough 
stimulation of the immune system achieved by 
vaccination. 
In general, stimulatory effects of Freund’s adjuvant 
to increase production of antibodies were seen, but 
some instability of the produced antibody in 
second sampling was demonstrated.  
 






    So often stimulation of cells through application 
of HSP90 together with antigen occurs only locally 
and leading forward to IFNγ, IL-5 and IgG2a 
production, and no accordance of hypersensitivity 
reactions, but in the case of freund’s adjuvants also 
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